• "They say that about every CEO. It's a handle, a lightning rod, people get excited about it. The board decided my compensation. I did not."

-Enzon's chairman and CEO Jeffrey H. Buchalter, commenting on shareholder complaints about his salary

• "The dialogue is always out in the open, as opposed to the FDA, where you respond to questions but you have no idea if they're the right answers or the answers they're looking for."

-Anthony DiTonno, CEO of NeurogesX Inc., comparing the European MAA regulatory process to the U.S.

• "It's always hard to second-guess pharma."

-Derek Jellinek, analyst with Boenning & Scattergood Inc., commenting 06/22/09 on Merck KGaA's decision to start a potentially risky Phase III trial with Oncothyreon Inc.'s vaccine Stimuvax in breast cancer